Cancer Immunotherapy at the Crossroads

How Tumors Evade Immunity and What Can Be Done

  • James H. Finke
  • Ronald M. Bukowski

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Basic Mechanisms of Immune Evasion

    1. Front Matter
      Pages 1-1
    2. Michael Campoli, Chien-Chung Chang, Xin-Hui Wang, Soldano Ferrone
      Pages 3-34
    3. Augusto C. Ochoa, Paulo C. Rodriguez, Jovanny Zabaleta, Pelayo Correa, Arnold H. Zea
      Pages 35-48
    4. Zoya R. Yurkovetsky, Irina L. Tourkova, Levent Balkir, Lori Perez, Galina V. Shurin, Gurkamal S. Chatta et al.
      Pages 49-65
    5. Tomohide Tatsumi, Amy Wesa, James H. Finke, Ronald M. Bukowski, Walter J. Storkus
      Pages 67-86
    6. Koji Tamada, Lieping Chen
      Pages 87-99
    7. Hannah Rabinowich, Brian R. Gastman
      Pages 101-117
    8. Ithaar H. Derweesh, Luis Molto, Charles Tannenbaum, Patricia Rayman, Christina Moon, Cynthia Combs et al.
      Pages 119-144
    9. Arvin S. Yang, Edmund C. Lattime
      Pages 157-172
    10. Andrew D. Weinberg, Dean E. Evans, Arthur A. Hurwitz
      Pages 173-194
    11. Peter A. Cohen, Gregory E. Plautz, James H. Finke, Suyu Shu
      Pages 195-213
    12. Robert G. Uzzo, Paul Cairns, Nickolai Dulin, Eric M. Horwitz, Alan Pollack, Vladimir Kolenko
      Pages 215-234
  3. Clinical Relevance of Immune Evasion

    1. Front Matter
      Pages 235-235
    2. Thomas Zander, Daniel Re, Michael von Bergwelt-Baildon, Jürgen Wolf, Joachim L. Schultze
      Pages 295-314
    3. Arjan Diepstra, Ewerton M. Maggio, Anke van den Berg, Sibrand Poppema
      Pages 315-334
    4. Steven M. Dubinett, Sherven Sharma, Min Huang, Jenny T. Mao, Raj K. Batra
      Pages 335-350
    5. Lucinda H. Elliott, Lorri A. Morford, William H. Brooks, Thomas L. Roszman
      Pages 351-371
  4. Back Matter
    Pages 373-386

About this book


The growing evidence that tumors can evade the immune system through a variety of mechanisms makes understanding these processes critical to implementing new and more effective forms of immunotherapy. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done, leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors) that may serve as biomarkers for patient prognosis. They discuss the means by which immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells are also outlined.
State-of-the-art and insightful, Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors.


apoptosis brain tumors carcinoma cell immunotherapy lymphocytes lymphoma renal cell carcinoma transplantation tumor

Editors and affiliations

  • James H. Finke
    • 1
  • Ronald M. Bukowski
    • 2
  1. 1.Department of Immunology, Lerner Research InstituteCleveland Clinic FoundationClevelandUSA
  2. 2.Experimental Therapeutics Program, Taussig Cancer CenterCleveland Clinic FoundationClevelandUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology